Category: Clinical Trials

A new first-in-human clinical trial has begun evaluating VVD-133214, an investigational oral therapy designed to target the Werner (WRN) protein in patients with advanced solid tumors that are microsatellite instability (MSI) high and/or deficient mismatch repair (dMMR). This Phase I study represents an exciting step forward in precision oncology, as it explores a novel biological pathway that may help control the growth of these specific cancer types.

The WRN protein has emerged as a promising target in cancer research because certain tumors—particularly those with MSI or dMMR characteristics—appear to rely on WRN for their survival and growth. By selectively acting on this protein, VVD-133214 is designed to interfere with the growth mechanisms of cancer cells while potentially sparing healthy tissue that doesn’t share the same vulnerability. This kind of targeted approach reflects the ongoing evolution of cancer treatment toward therapies that are more precisely matched to a tumor’s underlying biology.

The trial is structured as a dose-escalation and dose-expansion study, meaning researchers will first determine safe and effective dosing levels before expanding to evaluate the drug’s potential anti-tumor activity in larger patient groups. Notably, the study will assess VVD-133214 not only as a standalone treatment but also in combination with two well-established cancer therapies: bevacizumab, an anti-angiogenic agent, and pembrolizumab, a checkpoint inhibitor immunotherapy. Testing combination approaches from an early stage reflects a thoughtful strategy that could accelerate the identification of effective treatment regimens for patients with limited options.

This multicenter, open-label design allows researchers across multiple sites to gather comprehensive data on safety, pharmacokinetics, and early signals of efficacy in real-world clinical settings. For patients with MSI and dMMR advanced solid tumors—cancers that often present significant treatment challenges—the initiation of this trial offers a meaningful opportunity to access an innovative therapeutic approach while contributing to the broader scientific understanding of WRN-targeted treatments.

As with all early-phase clinical research, it will take time before definitive conclusions can be drawn about the safety and effectiveness of VVD-133214. However, the launch of this study highlights the continued innovation in the field of precision oncology and the ongoing efforts to develop new tools in the fight against difficult-to-treat cancers. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

A new clinical trial (NCT06717347) has been launched to evaluate a promising combination therapy for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL), one of the most common forms of non-Hodgkin lymphoma. The study will investigate whether adding zilovertamab vedotin, also known as MK-2140, to an established chemotherapy regimen can improve outcomes compared to standard treatment alone.

The trial design compares two treatment approaches: the experimental combination of zilovertamab vedotin with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP), versus the current standard-of-care regimen known as R-CHOP, which includes vincristine instead of the investigational peptide-drug conjugate. This head-to-head comparison will help researchers determine whether the newer combination offers meaningful advantages for patients facing this diagnosis.

Zilovertamab vedotin represents an innovative approach in cancer treatment, functioning as an antibody-drug conjugate that targets specific markers on cancer cells while delivering a cytotoxic payload directly to the tumor. This targeted mechanism is designed to potentially improve treatment precision while working alongside established chemotherapy drugs that have long been trusted in lymphoma care.

The primary goal of this research is to determine if participants receiving the new combination therapy experience longer periods without cancer growth or spread compared to those on the traditional regimen. For the DLBCL community, this type of investigation into refined treatment protocols represents continued progress in the ongoing effort to improve survival outcomes and quality of life for patients navigating this aggressive form of lymphoma.

Clinical trials like this one are essential steps in the advancement of cancer therapeutics, offering structured, monitored pathways for evaluating whether new combinations can outperform existing standards. As enrollment moves forward, this study adds to the growing body of research exploring how antibody-drug conjugates and peptide-based therapies might enhance traditional chemotherapy approaches. Patients and healthcare providers interested in learning more about trial eligibility and locations can find additional details through the official clinical trials registry.

This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance on treatment options.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

A new clinical trial listed on ClinicalTrials.gov is set to investigate whether Xeomin® (incobotulinumtoxinA) injections can help reduce the frequency of episodic migraine attacks. The study will compare Xeomin injections into muscles of the head and neck against a placebo, with the primary goal of measuring changes in monthly migraine days over the course of treatment.

The trial is designed with a thoughtful, patient-friendly structure spanning roughly 52 to 55 weeks. Participants will undergo a screening period of about 4 to 5 weeks, followed by four treatment sessions spaced approximately 12 weeks apart. In total, participants will have 14 visits, but notably, only six of these require an in-person, on-site appointment — the first visit, the last visit, and the four treatment sessions. The remaining eight check-ins can be completed remotely via phone or video call, which may make participation more manageable for people balancing migraine symptoms with everyday responsibilities.

Episodic migraine affects many people worldwide, often disrupting work, family life, and overall well-being. Research efforts like this one are valuable because they aim to build a stronger evidence base around treatment options that could help reduce the burden of recurring migraine days. By directly comparing Xeomin to a placebo, researchers can more clearly determine whether the treatment offers meaningful benefits beyond what might be expected from other factors.

The inclusion of a robust remote monitoring component also reflects a broader positive trend in clinical research: making trials more accessible and less burdensome for participants, without compromising the quality or rigor of data collection. This approach may help more people with migraine consider participating in research that could ultimately expand treatment options.

While results from this trial are not yet available, its launch represents another step forward in the ongoing effort to better understand and address episodic migraine. As with any clinical trial, outcomes will need to be evaluated once the study is complete. This article is for informational purposes only and is not medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine

A newly launched Phase 3 clinical trial is investigating a promising new treatment approach for patients battling refractory metastatic colorectal cancer (mCRC), one of the most challenging forms of the disease to treat once standard therapies have been exhausted. The study will evaluate telisotuzumab adizutecan, an investigational antibody-drug conjugate, in combination with bevacizumab, comparing it against the current standard of care regimen of trifluridine/tipiracil (LONSURF) plus bevacizumab.

Colorectal cancer remains the third most commonly diagnosed cancer worldwide, and patients whose disease progresses despite existing therapies often have few remaining options. The introduction of this large-scale trial, enrolling up to approximately 990 participants across roughly 125 sites globally, reflects a significant and encouraging investment in expanding the treatment landscape for this patient population. Antibody-drug conjugates like telisotuzumab adizutecan represent an innovative class of therapy designed to deliver cancer-fighting agents more precisely to tumor cells, potentially improving outcomes while working to manage side effects.

This Phase 3 study builds on earlier research into telisotuzumab adizutecan and is structured to directly compare its effectiveness and safety against a well-established standard of care. Participants will be randomly assigned to one of two treatment arms, with researchers closely monitoring disease activity, adverse events, and overall participant wellbeing through regular medical assessments, blood tests, and questionnaires over the course of the roughly 36-month study. This rigorous, head-to-head design is exactly the kind of methodical approach needed to determine whether a new therapy can genuinely improve upon existing options.

The global scale of this trial also underscores the collaborative, worldwide effort being mobilized to address unmet needs in oncology. By involving multiple sites and a substantial number of participants, researchers aim to generate robust, statistically meaningful data that could ultimately inform future treatment guidelines if the investigational therapy demonstrates meaningful benefits. For patients and families facing refractory mCRC, the advancement of new therapies into late-stage clinical testing offers a meaningful sense of progress and possibility.

While it will take time before results from this trial are available, the initiation of this Phase 3 study marks an important step forward in the ongoing effort to develop more effective treatments for advanced colorectal cancer. This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Researchers have launched a new clinical trial, registered as NCT07817875 under Master Protocol J4M-MC-PWMP, to study tirzepatide (marketed under the brand name LY3298176) in children ages 6 to less than 12 who are living with obesity. Known as ADVANCE-SURMOUNT-KIDS, the study aims to determine whether the medication can safely and effectively support healthier growth trajectories when combined with lifestyle interventions, adding to the growing body of research on peptide-based therapies for pediatric health.

Tirzepatide has already shown encouraging results in adult populations for weight management and metabolic health, and this trial represents a thoughtful, carefully structured step toward understanding its potential in younger age groups. The study will evaluate not just efficacy, but also safety and pharmacokinetics — meaning researchers will closely track how the drug moves through and affects the body in children, an important consideration given physiological differences between kids and adults.

Participants will be enrolled for approximately 104 weeks in the primary study phase, during which they will receive either tirzepatide or a placebo alongside guidance on healthy lifestyle habits. This structure allows scientists to compare outcomes rigorously while ensuring every participant benefits from foundational lifestyle support regardless of which group they are assigned to.

Notably, the trial includes an extension option: children who complete the initial 104-week period, plus a 4-week safety follow-up, will have the opportunity to continue receiving tirzepatide for an additional 156 weeks while maintaining their lifestyle program. This extended-access design reflects a commitment to understanding long-term effects and gives families a sustained pathway to potential support rather than an abrupt end to treatment after the primary study concludes.

Childhood obesity remains a significant public health challenge, and treatment options tailored specifically for younger populations have historically been limited. Trials like ADVANCE-SURMOUNT-KIDS represent meaningful progress toward filling that gap with rigorous, safety-focused science. As the study progresses, it will contribute valuable data that could help inform future pediatric care approaches, potentially expanding safe and effective options for children and their families.

This article is for informational purposes only and is not intended as medical advice. Individuals interested in this or any clinical trial should consult qualified healthcare providers and refer to official trial resources for detailed information.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

Researchers are exploring new ways to make life easier and safer for kidney transplant recipients. A clinical trial listed on ClinicalTrials.gov is examining whether Nulojix® (belatacept), a biologic therapy, can be used to help patients avoid two categories of drugs long associated with tough long-term side effects: calcineurin inhibitors (CNIs) and steroids.

For decades, CNIs and steroids have been mainstays of anti-rejection therapy after kidney transplantation. While effective at preventing organ rejection, these medications are also linked to complications such as kidney toxicity, high blood pressure, bone loss, and metabolic changes over time. The goal of this study is to see whether belatacept-based regimens can maintain strong protection for the transplanted kidney while potentially sparing patients from some of these long-term burdens.

The trial’s design reflects a broader and encouraging trend in transplant medicine: moving toward smarter, more targeted immune therapies that reduce collateral damage to other organs and systems. By focusing on optimizing how belatacept is used, researchers hope to identify treatment approaches that support both the survival of the transplanted kidney and the overall long-term health of the patient.

Studies like this matter because kidney transplant recipients often face a lifelong balancing act — suppressing the immune system enough to prevent rejection, without causing harm through the very medications meant to protect them. If optimized belatacept protocols can reduce reliance on CNIs and steroids, it could represent a meaningful step forward in making post-transplant care gentler and more sustainable over time.

While results of this specific study aren’t detailed here, the fact that researchers are actively working to refine and improve transplant medication strategies is a positive sign for the field. Continued investigation into alternatives like belatacept underscores the transplant community’s commitment to improving quality of life for patients well beyond the initial surgery.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

A new Phase 2/3 clinical trial has begun enrolling treatment-naïve pediatric participants with achondroplasia, the most common form of dwarfism, to evaluate an investigational peptide therapy called BMN 333. The multicenter, multinational study is designed as a randomized, active-controlled trial, comparing BMN 333 directly against vosoritide, a peptide therapy already approved and used to help support bone growth in children with this condition.

Achondroplasia is caused by a genetic mutation that affects cartilage-to-bone conversion, leading to shortened limbs and other skeletal differences. Vosoritide, developed by BioMarin, was among the first therapies to target the underlying growth signaling pathway involved in the condition, offering families a treatment option beyond monitoring and orthopedic management. The introduction of BMN 333 as a next-generation candidate suggests continued investment in refining and potentially improving upon existing peptide-based approaches for this population.

What makes this trial notable is its “operationally seamless” design, allowing the study to progress from Phase 2 into Phase 3 without unnecessary delays between stages. This adaptive structure can help accelerate the overall development timeline, meaning that if early data are encouraging, researchers can move more efficiently toward gathering the larger dataset needed for potential regulatory review. For families navigating achondroplasia, faster and more streamlined trial pathways can translate into earlier access to new or improved treatment options.

The direct, active-controlled comparison to vosoritide is also a meaningful aspect of the trial design. Rather than testing BMN 333 against a placebo alone, researchers are positioning it alongside a treatment already known to be effective, which can offer clearer insight into how the new candidate performs in real-world-relevant terms. This kind of head-to-head evaluation reflects a maturing field of peptide therapeutics for skeletal growth conditions, where the goal is no longer simply proving a concept works, but refining and improving upon established benefits.

While results from this study are still to come, the initiation of this trial reflects ongoing momentum in achondroplasia research and the broader development of peptide-based therapies aimed at improving quality of life for children with genetic growth conditions. Continued clinical investigation like this is an encouraging sign for families and clinicians hopeful for expanded, well-studied treatment choices in the future.

This article is for informational purposes only and is not intended as medical advice.

Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

Source: Clinical Trial: Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia